Torrent Pharmaceuticals Limited

NSEI:TORNTPHARM Stock Report

Market Cap: ₹1.2t

Torrent Pharmaceuticals Valuation

Is TORNTPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TORNTPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.75k
Fair Value
102.9% overvalued intrinsic discount
26
Number of Analysts

Below Fair Value: TORNTPHARM (₹3548.3) is trading above our estimate of fair value (₹1749.14)

Significantly Below Fair Value: TORNTPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TORNTPHARM?

Key metric: As TORNTPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TORNTPHARM. This is calculated by dividing TORNTPHARM's market cap by their current earnings.
What is TORNTPHARM's PE Ratio?
PE Ratio59.9x
Earnings₹20.02b
Market Cap₹1.20t

Price to Earnings Ratio vs Peers

How does TORNTPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for TORNTPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.6x
CIPLA Cipla
23.4x2.61%₹1.3t
500124 Dr. Reddy's Laboratories
19.2x-1.14%₹1.1t
ZYDUSLIFE Zydus Lifesciences
22.8x-1.65%₹1.0t
500257 Lupin
25.1x4.49%₹927.7b
TORNTPHARM Torrent Pharmaceuticals
59.9x19.73%₹1.2t

Price-To-Earnings vs Peers: TORNTPHARM is expensive based on its Price-To-Earnings Ratio (59.9x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does TORNTPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
4.3xn/aUS$112.11m
524661 Welcure Drugs and Pharmaceuticals
3.3xn/aUS$9.71m
524652 Ind-Swift
0.3xn/aUS$9.69m
542724 Murae Organisor
4.5xn/aUS$7.72m
No more companies available in this PE range
TORNTPHARM 59.9xIndustry Avg. 31.4xNo. of Companies16PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TORNTPHARM is expensive based on its Price-To-Earnings Ratio (59.9x) compared to the Indian Pharmaceuticals industry average (31.4x).

Price to Earnings Ratio vs Fair Ratio

What is TORNTPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TORNTPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio59.9x
Fair PE Ratio44.2x

Price-To-Earnings vs Fair Ratio: TORNTPHARM is expensive based on its Price-To-Earnings Ratio (59.9x) compared to the estimated Fair Price-To-Earnings Ratio (44.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TORNTPHARM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹3,548.30
₹3,929.42
+10.74%
6.78%₹4,380.00₹3,425.00n/a26
Sep ’26₹3,584.30
₹3,929.42
+9.63%
6.78%₹4,380.00₹3,425.00n/a26
Aug ’26₹3,678.20
₹3,937.04
+7.04%
6.91%₹4,380.00₹3,425.00n/a26
Jul ’26₹3,416.70
₹3,660.50
+7.14%
7.49%₹4,232.00₹2,930.00n/a26
Jun ’26₹3,174.70
₹3,593.68
+13.20%
7.50%₹4,232.00₹2,930.00n/a28
May ’26₹3,322.00
₹3,612.18
+8.74%
8.11%₹4,232.00₹2,930.00n/a28
Apr ’26₹3,183.90
₹3,623.21
+13.80%
8.13%₹4,232.00₹2,930.00n/a28
Mar ’26₹2,948.10
₹3,639.83
+23.46%
7.71%₹4,232.00₹2,930.00n/a29
Feb ’26₹3,207.70
₹3,639.83
+13.47%
7.71%₹4,232.00₹2,930.00n/a29
Jan ’26₹3,418.55
₹3,525.55
+3.13%
12.30%₹4,232.00₹1,837.00n/a31
Dec ’25₹3,324.20
₹3,526.68
+6.09%
12.28%₹4,232.00₹1,837.00n/a31
Nov ’25₹3,205.30
₹3,530.23
+10.14%
12.24%₹4,232.00₹1,837.00n/a31
Oct ’25₹3,369.90
₹3,249.31
-3.58%
10.60%₹3,940.00₹1,837.00n/a32
Sep ’25₹3,485.15
₹3,240.88
-7.01%
10.75%₹3,940.00₹1,837.00₹3,584.3032
Aug ’25₹3,205.00
₹3,213.56
+0.27%
10.25%₹3,606.00₹1,837.00₹3,678.2032
Jul ’25₹2,781.20
₹2,842.06
+2.19%
10.04%₹3,337.00₹1,837.00₹3,416.7031
Jun ’25₹2,696.05
₹2,818.75
+4.55%
10.59%₹3,244.00₹1,837.00₹3,174.7032
May ’25₹2,642.55
₹2,707.81
+2.47%
11.14%₹3,063.00₹1,837.00₹3,322.0031
Apr ’25₹2,675.35
₹2,692.70
+0.65%
11.08%₹3,063.00₹1,837.00₹3,183.9030
Mar ’25₹2,668.65
₹2,669.57
+0.035%
11.06%₹2,975.00₹1,837.00₹2,948.1028
Feb ’25₹2,512.50
₹2,251.17
-10.40%
12.10%₹2,855.00₹1,805.00₹3,207.7029
Jan ’25₹2,296.30
₹2,142.93
-6.68%
8.01%₹2,480.00₹1,805.00₹3,418.5530
Dec ’24₹2,151.25
₹2,124.94
-1.22%
7.53%₹2,410.00₹1,805.00₹3,324.2031
Nov ’24₹1,920.05
₹2,119.40
+10.38%
7.46%₹2,410.00₹1,805.00₹3,205.3030
Oct ’24₹1,929.10
₹2,115.97
+9.69%
8.84%₹2,410.00₹1,750.00₹3,369.9029
Sep ’24₹1,785.80
₹2,098.40
+17.50%
9.14%₹2,410.00₹1,750.00₹3,485.1530
AnalystPriceTarget
Consensus Narrative from 26 Analysts
₹3.93k
Fair Value
9.8% undervalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/17 13:24
End of Day Share Price 2025/09/17 00:00
Earnings2025/06/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Torrent Pharmaceuticals Limited is covered by 57 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Ashwin MehtaAmbit Capital
Prashant NairAmbit Capital